resisttb
- Dec 1, 2021
- 1 min read

South Africa sets another example of success in beating tuberculosis

During the Union’s 52nd World Conference on Lung Health in late October, Doctors Without Borders (MSF) announced the results of TB-PRACTEAL, the first multi-country randomized controlled clinical trial to report on the efficacy and safety of a multidrug-resistant tuberculosis (MDR-TB) treatment. Time has shown that MDR-TB is a very difficult form of tuberculosis to treat, requiring multidrug therapies to be administered over a period of nine to 24 months. Read Here.

Recent Posts

See All

Genomic signatures of pre-resistance in Mycobacterium tuberculosis

Recent advances in bacterial whole-genome sequencing have resulted in a comprehensive catalog of antibiotic resistance genomic signatures in Mycobacterium tuberculosis. With a view to pre-empt the eme

New TB Funding Trends Report Finds that Funding for TB Research in 2020 Reached Only US$915 Million

New TB Funding Trends Report Finds that Funding for TB Research in 2020 Reached Only US$915 Million – Less Than Half of Investment Needed to End TB New York City/Geneva (December 9, 2021) – The new Tu

Global individual patient data platform for drug-resistant tuberculosis treatment

In order to increase the knowledge base for normative guidance on optimal treatment modalities for drug-resistant tuberculosis (DR-TB), WHO is announcing a publicly accessible global individual pati